Market Place
Sourcing Support
Revance Reports Q3 2024 Financial Results, Corporate Update
07 Nov 2024 //
BUSINESSWIRE
Revance Agrees To $924M Buyout By Crown Laboratories
13 Aug 2024 //
FIERCE PHARMA
Revance Reports Second Quarter 2024 Financial Results, Provides Corporate Update
08 Aug 2024 //
BUSINESSWIRE
Revance To Report Q2 2024 Results On August 8
01 Aug 2024 //
BUSINESSWIRE
Revance to Participate in Upcoming Investor Conferences
28 May 2024 //
BUSINESSWIRE
Revance introduces Daxxify for injection in US market for cervical dystonia
11 May 2024 //
PHARMABIZ
Revance Launches DAXXIFY For Cervical Dystonia In US
09 May 2024 //
BUSINESSWIRE
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
09 May 2024 //
BUSINESSWIRE
Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024
02 May 2024 //
BUSINESSWIRE
Revance Presenting New DAXXIFY® Data At AAN 2024
12 Apr 2024 //
BUSINESSWIRE
Revance Announces Pricing of $100.0 Million Public Offering of Common Stock
04 Mar 2024 //
BUSINESSWIRE
Revance Reports Fourth Quarter and Full Year 2023 Financial Results
28 Feb 2024 //
BUSINESSWIRE
Revance to Participate in Upcoming Investor Conferences
21 Feb 2024 //
BUSINESSWIRE
Revance to Release Fourth Quarter and Full Year 2023 Financial Results
21 Feb 2024 //
BUSINESSWIRE
Revance Receives Permanent J-Code for DAXXIFY®
02 Feb 2024 //
BUSINESSWIRE
Revance Provides Preliminary Fourth Quarter and Full Year 2023 Financial Results
08 Jan 2024 //
BUSINESSWIRE
Revance loses attempt to dismiss Botox trade secrets lawsuit
04 Jan 2024 //
ENDPTS
Analysts Just Slashed Their Revance Therapeutics, Inc. (NASDAQ:RVNC) EPS Numbers
10 Nov 2023 //
FINANCE YAHOO
Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update
08 Nov 2023 //
BUSINESSWIRE
Revance to Participate in Upcoming Investor Conferences
06 Nov 2023 //
BUSINESSWIRE
Revance to Release Third Quarter 2023 Financial Results on November 8, 2023
01 Nov 2023 //
BUSINESSWIRE
Revance Provides Corporate Update at Investor Day
19 Sep 2023 //
BUSINESSWIRE
Revance to Host Investor Day on September 19, 2023
22 Aug 2023 //
BUSINESSWIRE
Revance`s Botox rival gets FDA approval for painful neck muscle condition
15 Aug 2023 //
REUTERS
Revance Reports Second Quarter 2023 Financial Results, Provides Corporate Update
08 Aug 2023 //
BUSINESSWIRE
Revance to Release Q2 2023 Financial Results on Tuesday, August 8, 2023
01 Aug 2023 //
BUSINESSWIRE
Revance pushes Botox `breakup` in latest campaign for rival cosmetic drug
30 Jun 2023 //
ENDPTS
Revance to Participate in Upcoming Investor Conferences
23 May 2023 //
BUSINESSWIRE
Botox competitor Daxxify hits $15.4M in Q1 earnings as maker faces trade secrets
10 May 2023 //
ENDPTS
Revance Reports First Quarter 2023 Financial Results, Provides Corporate Update
09 May 2023 //
BUSINESSWIRE
AbbVie says Botox rival recruited its employees in bid to steal trade secrets
04 May 2023 //
FIERCE PHARMA
Revance to Participate in the Needham 22nd Annual Healthcare Conference
05 Apr 2023 //
BUSINESSWIRE
Revance Publishes its 2022 Environmental, Social, and Governance (ESG) Report
30 Mar 2023 //
BUSINESSWIRE
Revance to Participate in Upcoming Investor Conferences
07 Mar 2023 //
BUSINESSWIRE
Revance Reports Fourth Quarter and Full Year 2022 Financial Results
28 Feb 2023 //
BUSINESSWIRE
Revance Appoints Dr. Vlad Coric, M.D., as Independent Director
28 Feb 2023 //
BUSINESSWIRE
Revance to Participate in the 43rd Annual Cowen Healthcare Conference
27 Feb 2023 //
BUSINESSWIRE
Revance to Present Data on DAXXIFY for Injection for the Treatment of Cervical Dystonia
23 Feb 2023 //
BUSINESSWIRE
Revance to Release Fourth Quarter and Full Year 2022 Financial Results
21 Feb 2023 //
BUSINESSWIRE
Revance Provides an Update on DAXXIFY Commercial Launch
09 Jan 2023 //
BUSINESSWIRE
Revance to Participate in the 34th Annual Piper Sandler Healthcare Conference
22 Nov 2022 //
BUSINESSWIRE
Revance to Participate in the Stifel 2022 Healthcare Conference
09 Nov 2022 //
BUSINESSWIRE
Revance Reports Third Quarter 2022 Financial Results, Provides Corporate Update
08 Nov 2022 //
BUSINESSWIRE
Revance Announces Two Publications in The Aesthetic Surgery Journal
04 Nov 2022 //
BUSINESSWIRE
Revance to Release 3Q 2022 FYR on Tuesday, November 8, 2022
01 Nov 2022 //
BUSINESSWIRE
Revance Appoints David A. Hollander, M.D., M.B.A. as Chief Medical Officer
17 Oct 2022 //
BUSINESSWIRE
Revance to Present Data on the Efficacy & Safety of DAXXIFY for ASDS Meeting
10 Oct 2022 //
BUSINESSWIRE
Revance to Participate in the Guggenheim Nantucket Therapeutics Conference
21 Sep 2022 //
BUSINESSWIRE
Revance Announces Publications Highlighting the Efficacy Profile of DAXXIFY
19 Sep 2022 //
BUSINESSWIRE
Revance Announces Closing of Public Offering of the Underwriters’ Option
15 Sep 2022 //
BUSINESSWIRE
Revance Announces Proposed Public Offering of Common Stock
12 Sep 2022 //
BUSINESSWIRE
Revance Announces Pricing of $200.0 Mil Upsized Public Offering of Common Stock
12 Sep 2022 //
BUSINESSWIRE
U.S. FDA approves Revance`s Botox rival
09 Sep 2022 //
HEALTH ET
Revance Announces FDA Approval of DAXXIFY for Injection
08 Sep 2022 //
BUSINESSWIRE
FDA Issues Form 483 to Revance Therapeutics
18 Aug 2022 //
FDA
Revance slapped with another FDA citation, putting approval
11 Aug 2022 //
BIOPHARMADIVE
Revance slapped with another FDA citation.
10 Aug 2022 //
FIERCE PHARMA
Revance Reports Second Quarter 2022 Financial Results, Provides Corporate Update
09 Aug 2022 //
BUSINESSWIRE
